A recent phase IIa clinical trial has explored the potential of a short-acting psychedelic compound, DMT fumarate, as a treatment for major depressive disorder (MDD). Conducted by Small Pharma (now…
You can read the full story here: DMT for Depression: Phase 2 Trial Results & Safety Data.